Argenx Begins Phase 2 Trial of ARGX-110 for Cutaneous T-cell Lymphoma
News
A Phase 2 trial evaluating the anti-CD70 antibody ARGX-110 in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) has begun dosing participants, argenx announced. “We have previously observed evidence of ... Read more